Evidence map›Paper›PMID 27632214›Full record

ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2017

Predictive factors for functional improvement following intravitreal bevacizumab injections after central retinal vein occlusion.

Kai Januschowski, Nicolas Feltgen, Amelie Pielen, Bernhard Spitzer, Matus Rehak, Georg Spital, Spyridon Dimopoulos, Bevacizumab Study Group Venous Occlusion, Carsten H Meyer, Gesine B Szurman

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Predictive factors for functional improvement following intravitreal bevacizumab injections after central retinal vein occlusion.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2017
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 1 country.

Kai JanuschowskiEye Clinic Sulzbach, Knappschaftsklinikum Sulzbach Saar, An der Klinik 10, 66111, Sulzbach/Saar, Germany. Kai.januschowski@med.uni-tuebingen.de.
Nicolas FeltgenUniversity Eye Hospital, University of Goettingen, Goettingen, Germany.
Amelie PielenUniversity Eye Hospital, Hannover Medical School, Hannover, Germany.
Bernhard SpitzerDepartment of Education and Psychology, Freie Universität Berlin, Berlin, Germany.
Matus RehakAugenklinik Universitätsmedizin Berlin Charité, Campus Benjamin Franklin, Berlin, Germany.
Georg SpitalDepartment of Ophthalmology, St. Franziskus Hospital, Muenster, Germany.
Spyridon DimopoulosCentre for Ophthalmology, University Eye Clinic Tuebingen, Tuebingen, Germany.
Bevacizumab Study Group Venous Occlusion
Carsten H MeyerDepartment of Ophthalmology, University of Bonn, Bonn, Germany.
Gesine B SzurmanEye Clinic Sulzbach, Knappschaftsklinikum Sulzbach Saar, An der Klinik 10, 66111, Sulzbach/Saar, Germany.
Knappschaftsklinikum Saar · DEUniversity of Bonn · DEFreie Universität Berlin · DEMedizinische Hochschule Hannover · DESt. Franziskus Hospital · DESTZ eyetrial · DEUniversity Medical Center Freiburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeVision loss in central retinal vein occlusion (CRVO) is mostly caused by macular edema (ME) and can be treated with intravitreal bevacizumab injections. The goal of this study was to identify predictive factors for improvement in visual acuity.

methodsThree hundred and sixteen eyes of six centres having received intravitreal bevacizumab for ME due to CRVO were enrolled in this multicentre, retrospective, interventional case series. The follow-up time was 24 to 48 weeks. Investigated patient characteristics were pretreatment, duration of CRVO prior to the first injection, initial best-corrected visual acuity (BCVA), baseline central retinal thickness as measured by optical coherence tomography, gender, eye, age, comorbidity with glaucoma, systemic hypertension, or diabetes mellitus.

resultsMultiple regression analysis confirmed the following baseline predictive factors for an increase in visual acuity: low BCVA (p < 0.001), high CRT (p < 0.02), and treatment naïve patients (p = 0.03). None of the other investigated patient characteristics could be identified as prognostic factors for increase in visual acuity (p > 0.1).

conclusionsIntravitreal injections of bevacizumab in a routine clinical setting effectively improved and stabilized BCVA in CRVO. Our large multicenter study identified initial BCVA, baseline CRT, and pre-treatment as prognostic factors for visual improvement.

Indexed as

Recovery of FunctionAdultAgedAged, 80 and overAngiogenesis InhibitorsBevacizumabDose-Response Relationship, DrugFemaleFluorescein AngiographyFollow-Up StudiesFundus OculiHumansIntravitreal InjectionsMacular EdemaMaleMiddle AgedAngiogenesis InhibitorsBevacizumabBevacizumabCentral retinal vein occlusionIntravitreal injectionMacular edemaPrognostic factors

Identifiers

PMID27632214
OpenAlexW2507736196

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.